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Objectives: To identify qualitative VASARI (Visually AcceSIble Rembrandt Images)
Magnetic Resonance (MR) Imaging features for differentiation of glioblastoma (GBM)
and brain metastasis (BM) of different primary tumors.
Materials and Methods: T1-weighted pre- and post-contrast, T2-weighted, and T2-
weighted, fluid attenuated inversion recovery (FLAIR) MR images of a total of 239 lesions
from 109 patients with either GBM or BM (breast cancer, non-small cell (NSCLC)
adenocarcinoma, NSCLC squamous cell carcinoma, small-cell lung cancer (SCLC))
were included. A set of adapted, qualitative VASARI MR features describing tumor
appearance and location was scored (binary; 1 = presence of feature, 0 = absence of
feature). Exploratory data analysis was performed on binary scores using a combination of
descriptive statistics (proportions with 95% binomial confidence intervals), unsupervised
methods and supervised methods including multivariate feature ranking using either
repeated fitting or recursive feature elimination with Support Vector Machines (SVMs).
Results: GBMs were found to involve all lobes of the cerebrum with a fronto-occipital
gradient, often affected the corpus callosum (32.4%, 95% CI 19.1–49.2), and showed a
strong preference for the right hemisphere (79.4%, 95% CI 63.2–89.7). BMs occurred
most frequently in the frontal lobe (35.1%, 95% CI 28.9–41.9) and cerebellum (28.3%,
95% CI 22.6–34.8). The appearance of GBMs was characterized by preference for well-
defined non-enhancing tumor margin (100%, 89.8–100), ependymal extension (52.9%,
36.7–68.5) and substantially less enhancing foci than BMs (44.1%, 28.9–60.6 vs. 75.1%,
68.8–80.5). Unsupervised and supervised analyses showed that GBMs are distinctively
different from BMs and that this difference is driven by definition of non-enhancing tumor
margin, ependymal extension and features describing laterality. Differentiation of
histological subtypes of BMs was driven by the presence of well-defined enhancing
and non-enhancing tumor margins and localization in the vision center. SVM models with
optimal hyperparameters led to weighted F1-score of 0.865 for differentiation of GBMs
from BMs and weighted F1-score of 0.326 for differentiation of BM subtypes.December 2020 | Volume 10 | Article 5810371
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ependymal extension, and tumor localization may serve as potential imaging biomarkers
to differentiate GBMs from BMs.Keywords: qualitative magnetic resonance features, Visually AcceSIble Rembrandt Images, exploratory data
analysis, differentiation, glioblastoma, brain metastasis, machine learning, support vector machinesINTRODUCTION
Brain metastases (BMs) are the most common tumors of the
central nervous system (1, 2). With an incidence of about 5,000
newly diagnosed cases every year in Switzerland (3), they by far
exceed primary brain tumors (around 600 newly diagnosed cases
per year) (4). Among primary brain tumors, glioblastoma
multiforme (GBM), a very malignant form of diffusely
infiltrating WHO grade IV astrocytoma, is the most frequent
in adults (5).
BMs and GBMs have different growth patterns on a cellular
scale, with BMs usually presenting as well-defined spherical
lesions, which displace adjacent brain tissue without notable
infiltration (6) and GBMs mostly exhibiting invasive growth
patterns with infiltration of the surrounding structures, favorably
white matter tracts (7). Nevertheless, they may be hard to
distinguish on MR images, if no evident features such as
multiplicity for BM or transhemispheric spread for GBM is
present (8).
The morphology of brain tumors can be characterized in
different ways, for example through volumetric segmentation of
the tumor compartments (9), i.e. quantitative analysis, or by
characterization of qualitative features. Quantitative analysis
notably also includes the analysis of heterogeneity of brain
tumors which has been demonstrated to be an important
imaging biomarker for differentiation of cancerous tissues in
gliomas (10–12). For primary brain tumors a set of qualitative
features has been defined by a group of experienced
neuroradiologists from the cancer research community to
enable standardized scoring of subjective MR features, which
are regularly encountered on routine contrast-enhanced MR
images. This set is called the VASARI feature guide [Visually
AccesSIble REMBRANDT (The Repository of Molecular Brain
Neoplasia Data) Images], and it currently comprises 24
morphologic features, describing the location of the tumor,
characteristics of the tumor compartments, and presence of
distinct features such as hemorrhage or pial invasion (13–15).
Even before VASARI, researchers assessed the utility of such
information (16). For example already in 2005, Pope et al.
studied the relationship between 15 imaging variables and
survival in patients with grade III/IV gliomas (17), but the
VASARI feature guide allows radiologists to study and report
their findings in a standardized way, largely independent of the
rater, institution, and approach used (16).
The VASARI features have been employed for different
research questions, most commonly prediction of patient
survival (18–20) or prediction of tumor progression (21). Most
of these studies did not evaluate the predictive quality of2
VASARI features alone, but in combination with clinical,
pathological and/or molecular data. Some used the TCGA (The
Cancer Genome Atlas)-GBM dataset (13, 19, 22–24) as it
provides easily accessible and ready to use imaging data
including a variety of additional information about the
available patients (25).
Even though most commonly used to describe GBMs, the
VASARI features have also been applied to lower grade gliomas
(LGG): Hyare et al. tried to predict isocitrate dehydrogenase 1
(IDH1) mutation status (26), Zhou et al. aimed at predicting
histological grade and tumor progression as well as mutation
status (IDH1 and 1p/19q codeletion) (27) and Lehrer et al.
evaluated the relationship between MR tumor characteristics
and protein measurements (28).
So far, the VASARI feature set has only been applied to
primary brain tumors; its use in brain metastases has not been
evaluated. Consequently, this study explores the applicability
of the VASARI feature set in patients with BMs. The objective
is the identification of a subset of VASARI features for the
diagnostic discrimination among GBMs and BMs of different
primary tumors.MATERIALS AND METHODS
Study Population
Eligible for this study were patients admitted to the Inselspital
Bern between 2000 and 2018 with histologically confirmed
diagnosis of one of the following five brain pathologies: 1)
brain metastasis (BM) from carcinoma of the breast, 2) BM of
non-small cell (NSCLC) adenocarcinoma of the lung, 3) BM
NSCLC squamous cell carcinoma (SCC) of the lung, 4) small cell
carcinoma of the lung (SCLC), or 5) GBM. The collective of
eligible patients was reviewed for existence of pre-operative
MR images.
Initially, 119 patients with histologically confirmed BMs were
included. For the BM groups, exclusion occurred upon: one or
more of the four required MR sequences are unavailable (n = 23,
detailed in Section Imaging Protocol), poor image quality (n = 4),
previous tumor resection (n = 1), exclusively extra-axial lesions
(n = 6), and unmanageable number of metastases (>50, n = 1) (cf.
Figure 1). For every BM group we included all patients meeting
the inclusion and exclusion criteria, up to a maximum of 30
patients per group. In groups with more than 30 patients meeting
the criteria we gave preference to the ones who underwent
imaging more recently due to better imaging quality in recent
years. We were able to include a total of 84 BM patients: 30 with
BM from carcinoma of the breast, 13 with BM from NSCLC SCCDecember 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain Tumorsof the lung, 30 with BM from NSCLC adenocarcinoma of the
lung, and 11 with BM from SCLC.
25 GBM patients were included from a patient cohort
published previously in context of brain tumor segmentation
(29). Lesions which did not show any enhancing tumor
component or exhibited a very large proportion of non-
enhancing tumor were not considered in our analysis (in total
five lesions in four patients).
This led to a total of 109 included patients (84 with BM, 25
with GBM). The research described in this paper took place at
the Inselspital Bern, in the context of the trial CATCh, a single-
center retrospective cohort study without intervention, using MR
images which have been acquired in the process of clinical
diagnostics. CATCh has been approved by the local research
ethics commission (Kantonale Ethikkomission Bern).
Imaging Protocol
Due to the extensive time span of patient eligibility and images
being partly externally acquired, imaging protocols for BMs were
highly heterogeneous (parameter values are reported as ranges).
MR images were acquired on 1.5 or 3 T MR scanners from
Philips Medical Systems, Siemens and GE Medical Systems. Four
representative MR sequences were used: T2-weighted (T2), T2-
weighted with fluid attenuated inversion recovery (FLAIR),
native T1-weighted (T1) and T1-weighted with gadolinium
contrast-agent (T1c). Sequence parameters: T2) acquired as a
T2 SPACE iso-voxel sequence with a slice thickness of 1 mm in
sagittal direction or as spin-echo or turbo spin-echo sequence
with a slice thickness of 3–6 mm in axial direction, using an echo
time (TE) of 13–409 ms and a repetition time (TR) of 438–15,000
ms. FLAIR) acquired as T2 SPACE dark fluid iso-voxel sequence
with slice thickness 0.9 mm or 1.4 mm in sagittal direction or as
FLAIR-sequence with slice thickness 3–6 mm in coronary or
axial direction, TE 7.4–386 ms, TR 2,000–11,000 ms. T1)
acquired as gradient echo sequence with a slice thickness ofFrontiers in Oncology | www.frontiersin.org 31 mm in sagittal direction or as spin-echo sequence with a slice
thickness of 3–6 mm in axial direction, TE 1.5–17 ms, TR 164–
1,910 ms. T1c) acquired as gradient echo sequence with a slice
thickness of 0.9 or 1 mm in sagittal direction, T1 vibe iso-voxel
sequence with a slice thickness of 0.8 or 0.9 mm in transversal
direction or as spin-echo sequence with a slice thickness of 3–6
mm in axial direction, with gadolinium enhancement, TE 2.3–17
ms, TR 6.1–2,320 ms.
For the GBMs, a standardized MR protocol was used for all
patients. All sequences were acquired on a 1.5 T MR scanner from
Siemens (Siemens Avanto and Siemens Area, Siemens, Erlangen/
Germany). The protocol included T2) acquired as a 3D T2w SPACE
in sagittal direction, TE 380 ms, TR 3000 ms, FOV 256 × 256 mm2,
FA 120°, isotropic voxel size of 1 mm × 1 mm × 1 mm. FLAIR)
acquired as a 2D T2w FLAIR in axial direction, TE 80 ms, TR 8,000
ms, FOV 256 × 256mm2, FA 120°, anisotropic voxel size of 1 mm ×
1 mm × 3 mm. T1) acquired as native 3D T1w MPR in sagittal
direction, TE 2.67 ms, TR 1580 ms, FOV 256 × 256 mm2, FA 8°,
isotropic voxel size of 1 mm× 1mm× 1mm. T1c) acquired as a 3D
T1w sequence with gadolinium contrast enhancement in sagittal
acquisition, TE 4.57 ms, TR 2070 ms, FOV 256 × 256 mm2, FA 15°,
isotropic voxel size of 1 mm × 1 mm × 1 mm.
Visually AcceSIble Rembrandt Image
Magnetic Resonance Features
Based on the VASARI MR feature guide, we derived a set of
morphological features which were evaluated for a total of 239
individual brain lesions from 109 patients. The defined set
comprised localization-based features as well as appearance-
based features.
The localization-based features included the involvement of
-left/right hemisphere or central structure
-cerebral lobes: frontal, parietal, temporal and occipital lobe
-insular cortexFIGURE 1 | Inclusion of patients with brain metastases. The final number of included patients is n = 84.December 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain Tumors-subcortical structures: basal ganglia, thalamus, brainstem and
Corpus callosum
-cerebellum
-eloquent brain areas: vision center (area around Sulcus calcarinus),
auditory center (Gyri temporales transversi), Wernicke’s area (from
dorsal region of Gyrus temporalis superior to the Gyri angularis et
supramarginalis of the parietal lobe), Broca’s area (Partes
triangularis et opercularis of Gyrus frontalis inferior), primary
somatosensory cortex (Gyrus postcentralis) and primary
somatomotor cortex (Gyrus praecentralis).
The localization-based features were not treated as mutually
exclusive, but every lesion was attributed to multiple of the
above-mentioned categories, e.g. right hemisphere, temporal
lobe, vision center.
The appearance-based features included
-definition of contrast-enhancing margin (margin of contrast-
enhancing tumor compartment (CET), strongly T1c
hyperintense) and non-enhancing margin (margin of the non-
contrast enhancing tumor compartment [nCET]/peritumoral
edema, FLAIR/T2 hyperintense)
-existence of: hemorrhage, which was defined as T1
hyperintensity visible in both T1 native and T1c images, pial
invasion, ependymal invasion
-involvement of cortex
-crossing of brain midline by the CET and nCET
-multiplicity of enhancing foci.
We chose these features from the VASARI guide by excluding
semi-quantitative measurements (i.e. proportion of compartment
1 to compartment 2) and features that evaluate post-interventional
status, as we a priori excluded patients who already underwent
surgical treatment. Furthermore, very rarely observed features in
GBMs and BMs such as calvarian remodeling have been omitted.
In order to facilitate the rating of VASARI MR features, the
four MR sequences (T1, T1c, T2, FLAIR) were rigidly co-
registered using a versor 3D rigid transform optimized using
Mattes Mutual Information metric from the Insight Toolkit
(ITK) (30). The feature evaluation for all 239 lesions has been
consecutively performed by a medical student (AP) and was
subsequently confirmed by an experienced, board-certified
neuroradiologist with more than 8 years of experience in brain
tumor diagnostics (UPK).
Statistical Analysis
The aim of the exploratory data analysis was to identify patterns in
the data, which could serve as a basis for hypothesis formulation
and subsequent prospective confirmatory analysis. The VASARI
features correspond to asymmetric binary attributes (1 = presence
or 0 = absence of a feature). The presence of features for two lesions
implies that they are more similar to one another, while the absence
of features does not carry the same amount of information. Thus,
the VASARI features are considered as asymmetric binary
attributes. In the first phase, the features were counted, and
proportions were computed for each histological type separately.Frontiers in Oncology | www.frontiersin.org 4Proportions were visualized using heatmaps, and 95% binomial
confidence intervals for proportions were estimated using the
Wilson method (31). In the second phase, the localization-based
and appearance-based MR features were combined for an
unsupervised exploratory data analysis. Pairwise differences were
measured among binary feature vectors of all lesions and
histological subtypes using the Jaccard distance (=1 − Jaccard
index). The resulting distance matrix (of dimension 239 × 239)
was clustered using agglomerative hierarchical clustering with
average linkage. Furthermore, pairwise differences were
summarized across all lesions (by averaging) within a given
histological tumor type, to yield a distance matrix for the different
types. The resulting distance matrix was transformed to an affinity
matrix of an undirected graph by computing its entries ai,j = 1 − di,j
with di,j being the (i,j)
th-entry of the distance matrix. Finally, the
undirected graph is visualized using a spectral layout, which puts
nodes with high affinity closer to each other than nodes with low
affinity. This procedure was repeated for different VASARI feature
subsets. Subsets were generated by exclusion of features if they
exhibited proportions of less than X% across all histological tumor
types (with X ranging from 15 to 90%, in 15% increments). The
rationale for the exclusion is to remove features which do not carry
sufficient information for the purpose of tumor type differentiation.
In the third phase, the localization-based and appearance-basedMR
features were combined for a supervised exploratory data analysis,
which included the tumor class label in the computation.
Differentiation of BMs from GBMs was formulated as a binary
classification problem and differentiation among histological
subtypes of BMs as a multi-class problem (four classes).
Univariate feature ranking was performed using the Mutual
Information between feature values and tumor class labels.
Multivariate feature ranking was performed by repeatedly fitting a
linear soft-margin Support Vector Machine (SVM) to the data. In
each iteration, the hyperparameter C [with values (0.001, 0.01, 0.1, 1,
10, 100)] and/or class balancing (on/off) was changed, resulting in a
total of 12 models. Stratified 3-fold cross-validation with weighted-
F1-score as performance metric was performed to find the optimal
hyperparameter setting for the binary discrimination of BMs versus
GBMs and for the multi-class problem of discriminating the
histological subtypes of BMs. The latter was implemented in a
one-vs-all approach. Finally, based on the optimal hyperparameters,
feature ranking by recursive feature elimination was performed as
an additional multivariate method. Descriptive statistics were
computed using R (version 4.0.0) (32); unsupervised and
supervised feature analyses were implemented using Python’s
networkx (version 2.4) and scikit-learn (version 0.22.1) modules.RESULTS
Patient Characteristics
Among the 109 patients included in this study are 63 women and
46 men. This asymmetry is explained by the fact that there are
only women in the breast cancer group. According to the Swiss
Cancer League, there have been only around 50 cases of breast
cancer in men per year in the period of 2012–2016 (33). NSCLCDecember 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain TumorsSCC presented with an asymmetry as well, occurring in 10 men
and three women. The median age for all groups is 63.37 years,
with a minimum of 27.13 years (GBM) and a maximum of 81.92
years (breast cancer). For more detailed information, see Table 1.
In Figure 2, an exemplary BM of a NSCLC adenocarcinoma is
shown alongside an exemplary GBM case. Evidently both BM
and GBM can exhibit contrast-enhancing tumor, central




The proportions of localization-based MR features for GBMs
and BMs are shown in Figure 3. Whereas brain metastases
seemed equally distributed over both brain hemispheres (51.7%,
95% CI 44.9–58.5 vs. 49.3%, 95% CI 42.5–56.1), it appeared that
GBMs tend to be localized more often in the right hemisphere
(79.4%, 95% CI 63.2–89.7). They also affected central structures
more than brain metastases did, especially the thalamus (17.6%,
95% CI 8.3–33.5) and corpus callosum (32.4%, 95% CI 19.1–
49.2). We did not observe any cases where GBM appeared
infratentorially (in the cerebellum or brainstem). GBMsFrontiers in Oncology | www.frontiersin.org 5involved all lobes of the cerebrum, though with a slight fronto-
occipital gradient, the frontal lobe being affected most frequently
(47.1%, 95% CI 31.5–63.3) and the occipital lobe least frequently
(17.6%, 95% CI 8.3–33.5). The somatosensory cortex (Gyrus
postcentralis) was infiltrated by GBMs rather frequently (20.6%,
95% CI 10.3–36.8); no case of infiltration of the primary visual
cortex (area around Sulcus calcarinus) was observed. BMs
showed a preference for localization in the frontal lobe (35.1%,
95% CI 28.9–41.9) and cerebellum (28.3%, 95% CI 22.6–34.8).
Comparison of Histological Subtypes
In Figure 4, the proportions of localization-based MR features
are broken down for the different histological subtypes of BMs.
BMs from breast cancer occurred more frequently in the
cerebellum (33.3%, 95% CI 24.6–43.4) than any other type of
brain tumor. In case they were located supratentorially, they
involved the frontal lobe more often than any other lobe or
subcortical structure (31.2%, 95% CI 22.7–41.2). BMs from
NSCLC adenocarcinoma tumors seemed to have a slight
preference for the frontal lobe (34.4%, 95% CI 23.7–47).
NSCLC SCC metastases involved the occipital lobe (27.8%,
95% CI 12.5–50.9) and especially the visual system more oftenTABLE 1 | Characteristics of included patients (n = 109) with five different histological tumor types (breast cancer, NSCLC Adenocarcinoma, NSCLC SCC, SCLC, GBM).























Number of lesions 93 61 18 33 34December 2020 | Volume 10 |FIGURE 2 | Exemplary case of a solitary brain metastasis from a NSCLC adenocarcinoma (top row) shown alongside an exemplary glioblastoma case (bottom row).
In both cases, contrast-enhancing tumor, central necrosis, and peritumoral edema are visible.Article 581037
Meier et al. Exploration of MR Features in Brain Tumors(22.2%, 95% CI 9–45.2) than any other tumor type. NSCLC SCC
metastases have not been observed to occur in any central brain
structures such as brain stem, thalamus, and basal ganglia; also
no affection of the insula was noted. BMs of SCLC tumors
showed the strongest preference for the frontal lobe (51.5%
95% CI 35.2–67.5) but also occurred in subcortical structures
[basal ganglia (15.2%, 95% CI 6.7–30.9) but not thalamus].
Among all BMs, they involved the corpus callosum most often




Figure 5 shows the proportions of appearance-based MR
features for BMs and GBMs. When compared to BMs, GBMs
exhibited a varied appearance with strong preference for
ependymal extension (52.9%, 36.7–68.5 vs. 12.2%, 8.4–17.4),
hemorrhage (23.5%, 12.4–40 vs. 9.3%, 6–14) and slightly forFrontiers in Oncology | www.frontiersin.org 6meningeal invasion (67.6%, 50.8–80.9 vs. 51.7%, 44.9–58.5).
Furthermore, they were a lot less likely to show more than one
enhancing focus per patient than BMs were (44.1%, 28.9–60.6 vs.
75.1%, 68.8–80.5). The non-enhancing margin of the tumor
affected brain tissue, usually corresponding to the outline of
the peritumoral edema, was always well-defined in GBMs as
opposed to BMs (100%, 89.8–100 vs. 45.4%, 38.7–52.2).
Interestingly, crossing of the mid-line by enhancing tumor
parts was similarly less likely in GBMs than in BMs (14.7%,
6.4–30.1 vs. 5.4%, 3–9.4), and the enhancing margin of BMs was
no more likely to be well defined than the one of GBMs (92.7%,
88.3–95.5 vs. 97.1%, 85.1–99.5).
Comparison of Histological Subtypes
In Figure 6, the proportions of appearance-based MR features
are broken down for the different histological subtypes of BMs.
In general, the differences in appearance-based MR features
among BMs of different histological types seemed to be subtle.FIGURE 3 | Heatmap showing the proportions for the different localization-based MR features in case of brain metastases and glioblastoma. Each proportion
corresponds to the ratio: number of lesions with feature/total number of lesions of that class. Darker color indicates a larger proportion.FIGURE 4 | Heatmap showing the proportions for the different localization-based MR features broken down for the different histological subtypes of brain
metastases (SCLC, NSCLC SCC, NSCLC adenocarcinoma, mammacarcinoma). Each proportion corresponds to the ratio: number of lesions with feature/total
number of lesions of that class. Darker color indicates a larger proportion.December 2020 | Volume 10 | Article 581037
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meningeal invasion (72.2%, 95% CI 49.1–87.5) and ependymal
extension (22.2%, 95% CI 9–45.2), but they did not exhibit
hemorrhage in any evaluated case. SCLC tumor metastases
showed most often multiple enhancing foci (84.8%, 95% CI
69.1–93.3).
Unsupervised Analysis of Combined
Magnetic Resonance Features
Based on the previous results, features were incrementally
excluded (in 15% steps) if proportions were below a fixed
threshold (<15 to <90% across all histological tumor types). In
the case of the <15% threshold, the excluded features included
“insular”, “brainstem”, auditory center”, “Wernicke”, “Broca”,
“somatomotor”, and “CET crosses midline” (seven features: six
localization-based and one appearance-based feature). In
Supplementary Figure 1, the result of an agglomerativeFrontiers in Oncology | www.frontiersin.org 7hierarchical clustering of the reduced feature set (for <15%
threshold) is shown. The corresponding mean Jaccard distance
among the different primary tumors is shown in Table 2. The
NSCLC SCC BMs exhibited the lowest intra-class Jaccard
distance (0.508) among all histological subtypes, which
indicates that they appear to be more homogeneous. The
distance matrix for a given threshold (e.g. <15%) can be
transformed to an affinity matrix of an undirected graph and
visualized using a spectral layout (Figure 7). We can observe that
overall GBM and SCLC appear to be very different from the
remaining three histological subtypes. The same observation can
be made if all available features are used (see Figure 7, outer left).
With an increasing threshold, the nodes of NSCLC
adenocarcinoma and NSCLC SCC move closer towards GBM
and away from mammacarcinoma. For the <90% threshold, only
three appearance-based features remained: definition of
enhancing margin, definition of non-enhancing margin, andFIGURE 5 | Heatmap showing the proportions for the different appearance-based MR features in case of brain metastases and glioblastoma. Each proportion
corresponds to the ratio: number of lesions with feature/total number of lesions of that class. Darker color indicates a larger proportion.FIGURE 6 | Heatmap showing the proportions for the different appearance-based MR features broken down for the different histological subtypes of brain
metastases (SCLC, NSCLC SCC, NSCLC adenocarcinoma, mamma carcinoma). Each proportion corresponds to the ratio: number of lesions with feature/total
number of lesions. Darker color indicates a larger proportion.December 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain Tumorscortical involvement. In the case that only those features are
excluded, NSCLC SCC and SCLC trade their position when
compared to the previous configuration (with NSCLC Adeno,
NSCLC SCC, and mammacarcinoma forming a cluster) (cf.
Figure 7, bottom left).
Supervised Analysis of Combined
Magnetic Resonance Features
In Table 3, the results of the univariate ranking using mutual
information between feature values and target labels are shown
alongside the multivariate ranking using either repeated fitting
(varied hyperparameters) or recursive feature elimination (RFE,
using optimal hyperparameters) based on linear soft-margin
Support Vector Machines (SVMs). The features are ranked
according to their scores (or weights) from the most important
to the least important one. For differentiation of GBMs from
BMs, high scores for definition of non-enhancing margin,
ependymal extension, and features describing laterality were
observed in case of both univariate and multivariate analyses.
For differentiation of histological subtypes of BMs, high scores
for definition of enhancing and non-enhancing margin and
localization in the vision center appeared in case of both
univariate and multivariate analyses. In addition, Figures 8
and 9 show the results of the repeated fitting of the SVM
algorithm for different hyperparameter configurations. For
differentiation of GBMs from BMs, the central localization and
definition of non-enhancing margin were weighted consistently
high. A gridsearch based on 3-fold cross-validation using
all available features led to an optimal hyperparameter settingFrontiers in Oncology | www.frontiersin.org 8(C = 1, no class balancing) with a weighted F1-score of 0.865
for the differentiation of GBMs and BMs and an optimal
hyperparameter setting (C = 0.1, with class balancing) for the
differentiation of the BM subtypes with a weighted F1-score
of 0.326.DISCUSSION
In this study, we investigated the potential of the VASARI MR
feature guide in differentiating BMs of different primaries from
GBMs using localization-based and appearance-based features.
The VASARI MR feature guide has been developed for primary
brain tumors and has mostly been applied to GBMs (13, 18–24)
and in a few studies to lower grade gliomas (26–28). To the best
of our knowledge, this is the first study applying VASARI
features to BMs. An explorative approach was chosen as a first
evaluation of applicability of VASARI features in this setting.
We found that GBMs differ fromBMs both (i) in their preferred
localization and (ii) MR image appearance: i.) GBMs involved all
lobes of the cerebrum with slight fronto-occipital gradient, often
affected central structures and showed a strong preference for the
right hemisphere, whereas BMs occurred most frequently in the
frontal lobe and in the cerebellum. ii.) GBMs always exhibited a
well-defined non-enhancingmargin and appearedmore often than
BMs as solitary lesions and/or with ependymal extension.
Differences among BMs were very subtle; the only distinct finding
was thatNSCLC SCCmetastaseswere localized occipitally affecting
the vision center more often than any other type of BM.TABLE 2 | Mean Jaccard distance summarized for all lesions of a particular tumor type based on binary VASARI feature vectors (using the 15% threshold for
exclusion).
GBM Breast cancer NSCLC Adeno NSCLC SCC SCLC
GBM 0.522 0.651 0.621 0.616 0.640
Breast cancer 0.651 0.575 0.583 0.589 0.593
NSCLC Adeno 0.621 0.583 0.559 0.579 0.590
NSCLC SCC 0.616 0.589 0.579 0.508 0.605
SCLC 0.640 0.593 0.590 0.605 0.560December 2020 | Volume 10 | Article 5FIGURE 7 | Spectral embedding of the distance matrix for all tumor types and all VASARI features (outer left side); all features but tumor margins and cortical
involvement (bottom left), and for different feature exclusion thresholds (<15 to <90%, based on proportions).81037
Meier et al. Exploration of MR Features in Brain TumorsTABLE 3 | Results of univariate and multivariate feature ranking (repeated fitting or recursive feature elimination) for differentiation of brain metastases (BM) from
glioblastoma (GBM) as well as the differentiation of the four different histological BM subtypes (mammacarcinoma, NSCLC adenocarcinoma, NSCLC SCC, SCLC).
Univariate ranking (Mutual
information BM vs. GBM)
Multivariate ranking (linear soft-margin SVM, BM vs.
GBM, median weight for 12 models)
Multivariate ranking (RFE, linear soft-margin SVM, BM vs.
GBM, C=1, no class balancing)
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brainstemFrontiers in Oncology | www.frontiersin.org 9For the multi-class problem, the Support Vector Machine (SVM) was trained in a one-vs-all fashion (bold, black font = features which are consistently top-ranked).
The former corresponds to a binary classification problem, whereas the latter is a multi-class classification problem (four classes).December 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain TumorsUnsupervised analysis of combined MR features showed that
NSCLC adenocarcinoma and NSCLC SCC BMs appear to be
most similar and that this similarity is driven by the definition of
tumor margins and cortical involvement. Furthermore, GBM
appear to be distinctively different from all types of BMs for
different feature subsets. Supervised analysis of combined MR
features showed for differentiation of GBMs from BMs high
scores for definition of non-enhancing margin, ependymal
extension, and features describing laterality in case of both
univariate and multivariate analyses. For differentiation of
histological subtypes of BMs, high scores for definition ofFrontiers in Oncology | www.frontiersin.org 10enhancing and non-enhancing margin as well as localization in
the vision center appeared in the case of both univariate and
multivariate analyses. A gridsearch based on 3-fold cross-
validation using all features yielded an optimal model with
weighted F1-score of 0.865 for the differentiation of GBMs
from BMs. For the differentiation of all tumor types, the
optimal model led to a weighted F1-score of 0.326.
In the spirit of multiverse analysis (34), i.e. by viewing the
data from different statistical angles, the same features and
“feature families” have come up repeatedly, substantiating
suspicion that these might play a role in brain tumorFIGURE 8 | Result for repeated fitting of linear soft-margin Support Vector Machine (SVM) for a total of 12 different hyperparameter configurations. Higher median
SVM weights across different hyperparameter configurations indicate VASARI feature which are more important for differentiation of BMs from GBMs (dark blue =
localization-based features, gray = appearance-based features).FIGURE 9 | Result for repeated fitting of linear soft-margin Support Vector Machine (SVM) for a total of 12 different hyperparameter configurations. Higher median
SVM weights across different hyperparameter configurations indicate VASARI feature which are more important for differentiation of histological BM subtypes (4
classes) (dark blue = localization-based features, gray = appearance-based features).December 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain Tumorsdifferentiation: i.) definition of tumor margins, ii.) ependymal
extension, iii.) tumor localization including the involvement of
subcortical gray matter structures and laterality.
i. non-enhancing tumor margin: GBMs presented with well-
defined non-enhancing tumor margin more often than BMs.
Previously, brain lesions have been found to show
peritumoral edema if they are larger than ~9.5 mm in
diameter (35). GBMs are usually large at the time of
diagnosis, thus typically exhibiting extensive edema with a
well-defined margin. The extent of edema is constrained by
the surrounding gray matter structures (e.g. cortex), which
may also contribute to the increased perception of the
edema’s definedness. In our population, some BMs were
very small and did not exhibit any peritumoral edema;
therefore we argue that they also did not present with a
well-defined non-enhancing tumor margin. In a future
study, we plan to investigate the relationship between the
volume of edema and its radiological presentation.
Furthermore, qualitative differences in T2-weighted signal
alterations between high-grade gliomas and BMs have been
demonstrated previously with high-grade gliomas exhibiting
more frequently high signal intensity of the cortex for non-
enhancing tumor regions on T2-weighted FLAIR sequences
when compared to brain metastases (36). A third aspect
might be image quality. As for the GBMs in our study a
standardized imaging protocol was used; MR images of BMs
were acquired with a variety of different protocols.
Consequently, the comparability of the MR images suffered.
ii. ependymal extension: The dogma of the brain being a
quiescent organ without neuronal regenerative potential is
outdated. Multipotent, self-renewing neural stem cell
populations have been confirmed in the forebrain
subventricular zone (SVZ) and the subgranular zone
(SGZ) of the dentate gyrus. These populations are capable
of neurogenesis in the adult brain, and it is widely
acknowledged that glioma initiating cells arise from these
populations (37–40). Because of the close spatial proximity
of the SVZ to the lateral ventricles, the feature “ependymal
extension” might be viewed as a surrogate marker for the
involvement of the SVZ. This potentially explains why
ependymal extension was more often present in GBMs
than in BMs which emerge in the brain through
hematogenic spread of systemic tumor cells.
iii. localization: It is still unclear if and why BMs preferably arise
in certain localization of the brain. The most accepted
hypothesis is that the rate of metastases is proportional to
the blood flow in this area (41, 42). This hypothesis is in
accordance with our findings of bigger cerebral lobes
exhibiting more metastases. Moreover, BMs from breast
cancer seemed to have particular affinity to the cerebellum,
which has also previously been described in the literature
(43). Compared to BMs, GBMs occurred more often in
subcortical gray matter structures such as the basal
ganglia, involved the corpus callosum and presented with a
slight decreasing fronto-occipital gradient. This finding hasFrontiers in Oncology | www.frontiersin.org 11previously been described by Larjavaara et al. (44). whose
“findings indicate that gliomas arise mainly from the
anterior subcortical structures of the brain, with an excess
in the frontal and temporal lobes that is not accounted for by
tissue volume alone.” This can be explained by the close
spatial proximity of the previously discussed origin of glioma
initiating cells in the SVZ and SGZ. Furthermore,
radiographic atlases of GBMs showed high tumor
incidence in periventricular white matter regions and
found that laterality and involvement of the frontal lobe
may be related to underlying genetic and molecular
characteristics of the tumor (45).
In general, our results could be useful in defining a subset of
MR features that help radiologists to differentiate between GBMs
and BMs in a more structured manner. As especially GBMs
exhibit some distinct characteristics, it could be argued that in
the absence of these, BM becomes the more likely diagnosis.
Based on our observations, the differentiation of GBMs from
BMs using definition of non-enhancing margin, ependymal
extension and localization in the brain should be evaluated as
imaging biomarkers for differential diagnosis in an independent
confirmatory analysis.
Some limitations of the study should be noted. Despite the
extensive inclusion period (years 2000 through 2018), we
obtained only small sample sizes for rare types of BMs
(NSCLC SCC and SCLC with 13 and 11 patients, respectively)
which caused a class imbalance when compared to more
frequently occurring BMs (NSCLC adenocarcinoma and
mamma carcinoma with 30 included patients each). Aware of
this imbalance, we intended to compensate by applying statistical
techniques that account for different group sizes: i) we used
stratified cross-validation in order to ensure that the original
class distribution is maintained, ii) we use class-weighting as a
hyperparameter for the SVM to adapt it for handling imbalanced
classes, and iii) we use the weighted F1-score as performance
metric, which is computed for each class label independently and
weighted by its support thus providing a robust classification
metric for imbalanced data. Since the initial class distribution of
the four tumor types approximates their prevalence in clinical
routine and the class distribution is maintained throughout our
analysis, we obtain an estimation of the SVMs’ classification
performance in a setting which closely reflects the clinical
scenario. With the extensive inclusion period another issue
arose: the heterogeneity of imaging protocols and image
quality. At our institution, a standardized imaging protocol for
brain tumor patients exists since 2014. Therefore, available
images and image quality varied widely over the years. This
can potentially lead to failure to detect the smallest lesions or
slight alteration of lesion features. On the contrary, one can argue
that the features which were found most discriminative are so in
a manner robust to different image acquisition protocols.
The applied VASARI features were capable of effectively
highlighting differences between GBMs and BMs, which were
reflected in descriptive statistics, showing consistently large
inter-tumoral distances in unsupervised analyses, and highDecember 2020 | Volume 10 | Article 581037
Meier et al. Exploration of MR Features in Brain Tumorsweighted F1-score for binary discrimination in supervised
multivariate analyses. Definition of non-enhancing margin,
ependymal extension, and tumor localization seem to play a
major role. Regarding the differentiation between histological
types of BMs, differences were much less accentuated. They seem
to be driven mainly by definition of tumor margins, and
localization in the vision center.DATA AVAILABILITY STATEMENT
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